Europe - Euronext Amsterdam - AMS:PHARM - NL0010391025 - Common Stock
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 362.27M | 297.20M | 245.32M | 205.62M | 198.87M | |||
| Cost Of Goods | 36.36M | 35.00M | 25.00M | 17.56M | 21.14M | |||
| Gross Profit | 325.69M | 261.80M | 220.10M | 188.06M | 177.73M | |||
| Operating Expenses | 288.54M | 265.97M | 242.00M | 177.69M | 153.73M | |||
| Research and Development | 88.43M | 81.47M | 66.81M | 50.87M | 62.09M | |||
| Selling, General, and Administrative Expenses | 204.00M | 175.00M | 166.00M | 120.29M | 85.09M | |||
| Operating Income | 36.76M | -3.59M | -21.39M | 10.37M | 24.00M | |||
| Interest Income/Expense | -11.61M | 1.28M | -6.63M | -3.25M | 9.52M | |||
| Other Income/Expense | N/A | -1.15M | N/A | N/A | 0.00 | |||
| Non Recurring Items | N/A | -5.03M | 16.00M | 7.87M | -10.44M | |||
| Income Before Taxes | 14.76M | -8.49M | -12.00M | 14.99M | 23.08M | |||
| Income Tax | 14.66M | 3.35M | -1.46M | 1.31M | 7.08M | |||
| Net Income | 100.00K | -12.00M | -11.00M | 13.67M | 16.00M | |||
| EBITDA | 52.40M | 12.41M | -5.39M | 23.55M | 43.61M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.01 | -0.02 | -0.02 | 0.02 | 0.02 | |||
| Non GAAP EPS | -0.00 | -0.02 | -0.02 | N/A | 0.02 | |||
| Statistics | ||||||||
| Gross Profit Margin | 89.90% | 88.09% | 89.72% | 91.46% | 89.37% | |||
| Profit Margin | 0.03% | -4.04% | -4.48% | 6.65% | 8.04% | |||
| Operating Profit Margin | 10.15% | -1.21% | -8.72% | 5.04% | 12.07% | |||
All data in USD